CN111989099A - 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途 - Google Patents

作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途 Download PDF

Info

Publication number
CN111989099A
CN111989099A CN201980010752.7A CN201980010752A CN111989099A CN 111989099 A CN111989099 A CN 111989099A CN 201980010752 A CN201980010752 A CN 201980010752A CN 111989099 A CN111989099 A CN 111989099A
Authority
CN
China
Prior art keywords
solvate
pharmaceutically acceptable
compound
acceptable salt
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980010752.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·N·格雷科
M·J·科斯塔恩佐
J·彭
D·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Beta Pharma Inc
Original Assignee
Zhejiang Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharma Inc filed Critical Zhejiang Beta Pharma Inc
Publication of CN111989099A publication Critical patent/CN111989099A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980010752.7A 2018-01-29 2019-01-29 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途 Pending CN111989099A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
US62/623,516 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
CN111989099A true CN111989099A (zh) 2020-11-24

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980010752.7A Pending CN111989099A (zh) 2018-01-29 2019-01-29 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途

Country Status (15)

Country Link
US (1) US11352341B2 (https=)
EP (1) EP3746072B1 (https=)
JP (1) JP7337395B2 (https=)
KR (1) KR20200115583A (https=)
CN (1) CN111989099A (https=)
AU (1) AU2019211491B2 (https=)
BR (1) BR112020015405A2 (https=)
CA (1) CA3088381A1 (https=)
EA (1) EA202091450A1 (https=)
IL (1) IL275948A (https=)
MX (1) MX2020007959A (https=)
PH (1) PH12020551155A1 (https=)
SG (1) SG11202006748RA (https=)
TW (1) TW201940166A (https=)
WO (1) WO2019148161A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113507930A (zh) * 2019-01-29 2021-10-15 贝达医药公司 2h-吲唑衍生物作为脑癌和脑转移的治疗剂
CN116601155A (zh) * 2020-11-26 2023-08-15 成都赛璟生物医药科技有限公司 杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3654982A4 (en) 2017-07-18 2021-04-14 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
PL3806898T3 (pl) * 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
EP3911324A4 (en) 2019-01-18 2022-08-17 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
MX2021013531A (es) 2019-05-05 2022-02-11 Qilu Regor Therapeutics Inc Inhibidores de cdk.
EP4159728A4 (en) * 2020-06-22 2024-06-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. MANUFACTURING PROCESS FOR CDK4/6 INHIBITOR
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059670A1 (en) * 2003-07-11 2005-03-17 Pfizer Inc Isethionate salt of a selective CKD4 inhibitor
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
CN1956982A (zh) 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
US9796701B2 (en) 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
US9969719B2 (en) 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107286134B (zh) 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059670A1 (en) * 2003-07-11 2005-03-17 Pfizer Inc Isethionate salt of a selective CKD4 inhibitor
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN106687454A (zh) * 2014-07-24 2017-05-17 贝达医药公司 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h‑吲唑衍生物及其医疗用途
US20170210726A1 (en) * 2014-07-24 2017-07-27 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113507930A (zh) * 2019-01-29 2021-10-15 贝达医药公司 2h-吲唑衍生物作为脑癌和脑转移的治疗剂
CN113507930B (zh) * 2019-01-29 2025-01-10 贝达医药公司 2h-吲唑衍生物作为脑癌和脑转移的治疗剂
CN116601155A (zh) * 2020-11-26 2023-08-15 成都赛璟生物医药科技有限公司 杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂

Also Published As

Publication number Publication date
EP3746072B1 (en) 2023-04-12
US11352341B2 (en) 2022-06-07
AU2019211491B2 (en) 2024-03-14
IL275948A (en) 2020-08-31
US20210139459A1 (en) 2021-05-13
CA3088381A1 (en) 2019-08-01
KR20200115583A (ko) 2020-10-07
TW201940166A (zh) 2019-10-16
EP3746072A1 (en) 2020-12-09
PH12020551155A1 (en) 2021-06-07
BR112020015405A2 (pt) 2020-12-08
JP2021512161A (ja) 2021-05-13
MX2020007959A (es) 2020-09-18
AU2019211491A1 (en) 2020-07-30
EA202091450A1 (ru) 2021-01-14
EP3746072A4 (en) 2021-06-02
WO2019148161A1 (en) 2019-08-01
JP7337395B2 (ja) 2023-09-04
SG11202006748RA (en) 2020-08-28

Similar Documents

Publication Publication Date Title
CN111989099A (zh) 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途
JP6490215B2 (ja) サイクリン依存性キナーゼ（ｃｄｋ）阻害剤としての２−ｈ−インダゾール誘導体およびその治療上の使用
JP7181558B2 (ja) Ｅｇｆｒモジュレーターとしての置換２－アミノピリミジン誘導体
TWI704151B (zh) Ｅｒｋ抑制劑
US9890168B2 (en) 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
AU2019209475A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN107922350A (zh) 新的苯并咪唑化合物及其医药用途
TW202023548A (zh) 新穎噻唑衍生物以及其藥用可接受鹽類
HK40034278A (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
OA19873A (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof.
OA18720A (en) 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034278

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201124